Benefits
NCGS symptom improvement (clinical trial)
Published clinical trial in Clinical and Translational Gastroenterology: administration of the enzyme mixture significantly decreased the change in symptom questionnaire scores before and after gluten challenge vs placebo in NCGS patients without adverse events. In particular, gluten-induced incomplete evacuation feeling and headaches significantly improved. Foundational evidence for the NCGS application.
Alpha-gliadin 33-mer peptide digestion
GluteAX specifically targets the 33-mer α-gliadin peptide — the most immunogenic gluten peptide and primary trigger for both celiac disease and many NCGS symptoms. The 33-mer is particularly proline-rich and resists cleavage by gastric, pancreatic, and intestinal brush-border peptidases. GluteAX's specialized enzyme combination addresses this digestive gap.
Four-enzyme synergistic mechanism
Single-enzyme glutenase products are limited by individual enzyme cleavage preferences. GluteAX combines four enzymes from four different organisms — peptidase (A. oryzae), semi-alkaline protease (A. melleus), deuterolysin (P. citrinum), and cysteine protease (papaya). Multi-enzyme synergy achieves more complete gluten peptide hydrolysis than any single enzyme can.
Headache reduction (NCGS-specific)
The clinical trial specifically documented improvement in gluten-induced headaches in NCGS patients. Gluten-related headaches are a recognized but often-underrecognized NCGS symptom — distinct from migraine and tension headache etiologies. Addressing headaches alongside GI symptoms expands GluteAX's clinical relevance for NCGS sufferers.
Complete evacuation feeling improvement
Trial documented significant improvement in gluten-induced incomplete evacuation feeling — the sense that bowel movements are incomplete despite straining. The symptom is bothersome and quality-of-life impacting; addressing it directly supports consumer-relevant outcomes vs purely biomarker improvements. Combined with other GI symptom relief, supports overall gut comfort.
Safety profile — no adverse events
The NCGS clinical trial recorded no adverse events from the enzyme mixture. Microbial and plant enzymes have long food-application safety records — Aspergillus oryzae specifically has been used in food fermentation (soy sauce, miso, sake) for centuries. Papain (papaya cysteine protease) has extensive dietary supplement use record. Combined safety supports long-term use.
NCGS — a real and growing category
Non-celiac gluten sensitivity (NCGS) is a recognized clinical entity distinct from celiac disease — affecting estimated 0.5-6% of the general population (some surveys higher). NCGS sufferers experience real symptoms from gluten exposure but lack celiac autoimmune markers. GluteAX addresses this specific population that does NOT require strict gluten avoidance.
Mechanism of action
33-mer α-gliadin peptide digestion
The 33-mer fragment of wheat α-gliadin is the most immunogenic gluten peptide and primary trigger for gluten-related immune responses. Its high proline content (13 prolines in 33 amino acids) makes it resistant to standard gastric, pancreatic, and intestinal peptidases. GluteAX's specialized proline-cleaving enzymes target this peptide specifically.
Multi-enzyme proteolytic synergy
GluteAX's four enzymes (peptidase, semi-alkaline protease, deuterolysin, cysteine protease) target different peptide bonds and amino acid residues. Combined hydrolysis achieves more complete gluten peptide degradation than any single enzyme. Different enzymes also work at different pH levels along the GI tract — providing coverage from stomach through intestine.
Reduced GI inflammatory triggering
By breaking down gluten peptides before they reach the small intestine, GluteAX reduces the inflammatory triggering that drives NCGS symptoms. Mechanism is distinct from celiac disease (autoimmune via HLA-DQ2/DQ8) — NCGS appears to involve innate immune and gut barrier mechanisms rather than autoimmunity.
Gastric and intestinal stability
Effective oral glutenases must be resistant to gastric pH and human digestive enzymes — remaining active throughout digestion. GluteAX's microbial enzymes from Aspergillus and Penicillium species evolved for stability in various pH conditions, supporting bioactivity along the full GI tract where gluten digestion occurs.
Clinical trials
Randomized single-blind placebo-controlled crossover clinical trial evaluating the four-enzyme mixture in NCGS patients. Patients selected via demographic screening, medical evaluations, anti-gluten antibody tests, and gluten challenge tests. Gluten challenge with enzyme mixture vs placebo. Published in Clinical and Translational Gastroenterology (Ido H, Matsubara H, Kuroda M et al.).
Adults with confirmed non-celiac gluten sensitivity (NCGS) selected via screening. Crossover design.
Enzyme mixture significantly decreased the change in symptom questionnaire scores before and after gluten challenge vs placebo, without adverse events. Specifically improved gluten-induced incomplete evacuation feeling and headaches. Subjects strongly positive for both anti-transglutaminase and anti-gliadin antibodies showed effect. Established foundational evidence for the NCGS application.
Class evidence for glutenase enzymes targeting the 33-mer α-gliadin peptide. In vitro studies of various glutenase preparations including E40 (Penicillium) showing complete digestion of immunodominant α-gliadin peptides. Mechanistic foundation for the glutenase enzyme category in NCGS and celiac applications.
Not applicable — in vitro studies of gluten digestion and immune cell stimulation.
Multi-enzyme glutenase preparations can digest immunodominant α-gliadin peptides under gastrointestinal conditions. The 33-mer α-gliadin peptide is the most immunogenic gluten fragment. Proline-rich peptide composition makes endogenous enzymes insufficient — supplemental enzymes address this digestive limitation. Class evidence supports GluteAX's enzymatic approach to gluten sensitivity.